Gender and Atrial Fibrillation: Differences and Disparities

Atrial fibrillation (AF) is the most common clinically relevant supraventricular arrhythmia. AF is a leading risk factor for stroke and accounts for about one-third of all ischemic cerebrovascular events.1 The last two decades have witnessed a paradigm shift in the management of AF with the development of catheter ablation and improvements in anticoagulant therapies. In this review, we discuss gender-related differences and disparities in the pathophysiology, clinical presentation, and management of AF.

New analyses presented at aha 2017 show Repatha® (evolocumab) significantly reduced cardiovascular events in patients with peripheral artery disease and in patients with a history of heart attacks

Data Support Use of evolocumab to Reduce Risk of Recurrent Cardiovascular Events in Patients With History of Multiple Heart Attacks 
Additional Analysis Found That Patients With More Recent Heart Attacks Experienced Substantial Risk Reductions With evolocumab 
Evolocumab Benefit in Peripheral Artery Disease Patients
 Presented at AHA Scientific Sessions 2017 and Simultaneously  

Safety and Efficacy of Protected Cardiac Intervention: Clinical Evidence for Sentinel Cerebral Embolic Protection

As the field of interventional cardiology has grown, so too has interest in mitigating severe adverse outcomes such as stroke. Unfortunately, the risk of stroke is increased by many underlying disease conditions (atrial fibrillation, patent foramen ovale, carotid artery disease and other vascular disease affecting brain perfusion, etc.), making clear differentiation between cardiac intervention-related cerebral infarction and the effect of other coexisting factors very difficult.

Education and feedback improve use of stroke prevention drugs in atrial fibrillation (IMPACT-AF)

Barcelona, Spain – 28 Aug 2017: Education of healthcare providers and patients with atrial fibrillation has led to a 9% absolute increase in the use of anticoagulation therapies to reduce stroke, according to late-breaking results from the IMPACT-AF trial presented today in a Hot Line LBCT Session at ESC Congress (1) and published in the Lancet.

Contemporary Management of Stroke Prevention in Atrial Fibrillation Following the European Society of Cardiology Guidelines

Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).

Total Occlusion and Bifurcation Interventions & Simple Education Partnership

The TOBI / Simple Partnership:

In July 2016, Simple Education and TOBI entered into a unique partnership where selected live cases from the TOBI 2016 course would be hosted on the platform, we are pleased to introduce you to this world class content and this innovative medical education platform that is truly a leap forwards in how medical education is delivered.

Total Occlusion & Bifurcation Interventions (TOBI)

TOBI has three main missions.

Atrial Fibrillation, Cognitive Decline and Dementia

Atrial fibrillation (AF) is the most common clinically-significant arrhythmia in the world.1 It is estimated that, in the US alone, approximately 2.5 million people have AF, with the condition being 1.5 times more common in men than in women.2 Despite the decline in morbidity and mortality from cardiovascular diseases in general due to advances in prevention and treatment, AF has not followed a similar trend.

Identification of Patients at Risk of Stroke From Atrial Fibrillation

Atrial fibrillation (AF) is the most common clinically significant arrhythmia, with an overall prevalence of approximately 1 % in the general population.1 An estimated 2.3 million adults in the US have AF, and this number is projected to increase to 5.6 million by 2050.1 The most clinically important complication from AF lies in the risk for cardiac thrombus formation and systemic embolism.